

# Kai Miao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9494793/publications.pdf>

Version: 2024-02-01

24  
papers

532  
citations

758635

12  
h-index

713013

21  
g-index

27  
all docs

27  
docs citations

27  
times ranked

543  
citing authors

#	ARTICLE	IF	CITATIONS
1	ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	7
2	S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. <i>Nature Communications</i> , 2022, 13, 1481.	5.8	33
3	Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. <i>International Journal of Biological Sciences</i> , 2022, 18, 3019-3033.	2.6	54
4	FGFR2- $\beta$ -BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model. <i>Frontiers in Immunology</i> , 2022, 13, 861221.	2.2	0
5	High-throughput membrane-anchored proteome screening reveals $\alpha$ -PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2022, 11, 3700-3713.	1.3	3
6	Mitochondrial genome undergoes de novo DNA methylation that protects mtDNA against oxidative damage during the peri-implantation window. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	12
7	Deciphering the autophagy regulatory network via single-cell transcriptome analysis reveals a requirement for autophagy homeostasis in spermatogenesis. <i>Theranostics</i> , 2021, 11, 5010-5027.	4.6	19
8	Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. <i>Nature Communications</i> , 2021, 12, 3046.	5.8	48
9	Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy. <i>Advanced Science</i> , 2021, 8, e2100974.	5.6	15
10	Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. <i>Theranostics</i> , 2021, 11, 9415-9430.	4.6	13
11	Patient-Derived Organoids Can Guide Personalized Therapies for Patients with Advanced Breast Cancer. <i>Advanced Science</i> , 2021, 8, e2101176.	5.6	42
12	Cancer drug screening with an on-chip multi-drug dispenser in digital microfluidics. <i>Lab on A Chip</i> , 2021, 21, 4749-4759.	3.1	22
13	Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing. <i>Theranostics</i> , 2021, 11, 9967-9987.	4.6	6
14	Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor. <i>Nature Communications</i> , 2020, 11, 4875.	5.8	24
15	Stagewise keratinocyte differentiation from human embryonic stem cells by defined signal transduction modulators. <i>International Journal of Biological Sciences</i> , 2020, 16, 1450-1462.	2.6	13
16	Imaging of macrophage mitochondria dynamics <i>in vivo</i> reveals cellular activation phenotype for diagnosis. <i>Theranostics</i> , 2020, 10, 2897-2917.	4.6	41
17	NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation. <i>Nature Communications</i> , 2020, 11, 3256.	5.8	56
18	BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis. <i>Advanced Science</i> , 2020, 7, 1903616.	5.6	39

#	ARTICLE	IF	CITATIONS
19	BRCA1 Deficiency: BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis (Adv. Sci. 6/2020). <i>Advanced Science</i> , 2020, 7, 2070033.	5.6	3
20	Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome. <i>Theranostics</i> , 2019, 9, 3952-3965.	4.6	16
21	BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy. <i>Human Molecular Genetics</i> , 2019, 28, 842-857.	1.4	10
22	Optimizing CRISPR/Cas9 technology for precise correction of the Fgfr3-G374R mutation in achondroplasia in mice. <i>Journal of Biological Chemistry</i> , 2019, 294, 1142-1151.	1.6	10
23	BRCA1 function in the intra-S checkpoint is activated by acetylation via a pCAF/SIRT1 axis. <i>Oncogene</i> , 2018, 37, 2343-2350.	2.6	15
24	CRISPR-Cas9: from Genome Editing to Cancer Research. <i>International Journal of Biological Sciences</i> , 2016, 12, 1427-1436.	2.6	31